Literature DB >> 26746191

Pivotal Role for CD16+ Monocytes in Immune Surveillance of the Central Nervous System.

Anne Waschbisch1, Sina Schröder2, Dana Schraudner2, Laura Sammet2, Babette Weksler3, Arthur Melms2, Sabine Pfeifenbring4, Christine Stadelmann4, Stefan Schwab2, Ralf A Linker2.   

Abstract

Monocytes represent a heterogeneous population of primary immune effector cells. At least three different subsets can be distinguished based on expression of the low-affinity FcγRIII: CD14(++)CD16 -: classical monocytes, CD14(++)CD16(+) intermediate monocytes, and CD14(+)CD16 ++: non-classical monocytes. Whereas CD16 -: classical monocytes are considered key players in multiple sclerosis (MS), little is known on CD16(+) monocytes and how they contribute to the disease. In this study, we examined the frequency and phenotype of monocyte subpopulations in peripheral blood, cerebrospinal fluid (CSF), and brain biopsy material derived from MS patients and controls. Furthermore, we addressed a possible monocyte dysfunction in MS and analyzed migratory properties of monocyte subsets using human brain microvascular endothelial cells. Our ex vivo studies demonstrated that CD16(+) monocyte subpopulations are functional but numerically reduced in the peripheral blood of MS patients. CD16(+) monocytes with an intermediate-like phenotype were found to be enriched in CSF and dominated the CSF monocyte population under noninflammatory conditions. In contrast, an inversed CD16(+) to CD16 -: CSF monocyte ratio was observed in MS patients with relapsing-remitting disease. Newly infiltrating, hematogenous CD16(+) monocytes were detected in a perivascular location within active MS lesions, and CD16(+) monocytes facilitated CD4(+) T cell trafficking in a blood -: brain barrier model. Our findings support an important role of CD16(+) monocytes in the steady-state immune surveillance of the CNS and suggest that CD16(+) monocytes shift to sites of inflammation and contribute to the breakdown of the blood-brain barrier in CNS autoimmune diseases.
Copyright © 2016 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26746191     DOI: 10.4049/jimmunol.1501960

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  40 in total

1.  Frontline Science: Buprenorphine decreases CCL2-mediated migration of CD14+ CD16+ monocytes.

Authors:  Matias Jaureguiberry-Bravo; Lillie Lopez; Joan W Berman
Journal:  J Leukoc Biol       Date:  2018-05-23       Impact factor: 4.962

2.  TLR10 suppresses the activation and differentiation of monocytes with effects on DC-mediated adaptive immune responses.

Authors:  Nicholas J Hess; Christopher Felicelli; Jennifer Grage; Richard I Tapping
Journal:  J Leukoc Biol       Date:  2017-02-24       Impact factor: 4.962

3.  Peripheral Blood Monocyte Tolerance Alleviates Intraperitoneal Lipopolysaccharides-Induced Neuroinflammation in Rats Via Upregulating the CD200R Expression.

Authors:  Liping Xia; Xin Xie; Yang Liu; Xiaoguang Luo
Journal:  Neurochem Res       Date:  2017-06-29       Impact factor: 3.996

Review 4.  Myeloid cells - targets of medication in multiple sclerosis.

Authors:  Manoj K Mishra; V Wee Yong
Journal:  Nat Rev Neurol       Date:  2016-08-12       Impact factor: 42.937

5.  IL-1β enables CNS access to CCR2hi monocytes and the generation of pathogenic cells through GM-CSF released by CNS endothelial cells.

Authors:  Alexandre Paré; Benoit Mailhot; Sébastien A Lévesque; Camille Juzwik; Prenitha Mercy Ignatius Arokia Doss; Marc-André Lécuyer; Alexandre Prat; Manu Rangachari; Alyson Fournier; Steve Lacroix
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-22       Impact factor: 11.205

6.  Monocyte NOTCH2 expression predicts IFN-β immunogenicity in multiple sclerosis patients.

Authors:  Marsilio Adriani; Petra Nytrova; Cyprien Mbogning; Signe Hässler; Karel Medek; Poul Erik H Jensen; Paul Creeke; Clemens Warnke; Kathleen Ingenhoven; Bernhard Hemmer; Claudia Sievers; Raija Lp Lindberg Gasser; Nicolas Fissolo; Florian Deisenhammer; Zsolt Bocskei; Vincent Mikol; Anna Fogdell-Hahn; Eva Kubala Havrdova; Philippe Broët; Pierre Dönnes; Claudia Mauri; Elizabeth C Jury
Journal:  JCI Insight       Date:  2018-06-07

Review 7.  Role of the JAK/STAT signaling pathway in regulation of innate immunity in neuroinflammatory diseases.

Authors:  Zhaoqi Yan; Sara A Gibson; Jessica A Buckley; Hongwei Qin; Etty N Benveniste
Journal:  Clin Immunol       Date:  2016-10-03       Impact factor: 3.969

8.  Complement 3a receptor in dorsal horn microglia mediates pronociceptive neuropeptide signaling.

Authors:  Suzanne Doolen; Jennifer Cook; Maureen Riedl; Kelley Kitto; Shinichi Kohsaka; Christopher N Honda; Carolyn A Fairbanks; Bradley K Taylor; Lucy Vulchanova
Journal:  Glia       Date:  2017-08-29       Impact factor: 7.452

9.  Exosomes From Subjects With Multiple Sclerosis Express EBV-Derived Proteins and Activate Monocyte-Derived Macrophages.

Authors:  May F Mrad; Esber S Saba; Layane Nakib; Samia J Khoury
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-05-18

10.  Selective Immunomodulatory and Neuroprotective Effects of a NOD2 Receptor Agonist on Mouse Models of Multiple Sclerosis.

Authors:  Adham Fani Maleki; Giulia Cisbani; Nataly Laflamme; Paul Prefontaine; Marie-Michele Plante; Joanie Baillargeon; Manu Rangachari; Jean Gosselin; Serge Rivest
Journal:  Neurotherapeutics       Date:  2021-01-21       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.